Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ETRA, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Ipsoprubart (ELA026) | Secondary Hemophagocytic Lymphohistiocytosis (sHLH | Phase 2/3 · NCT05416307 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ETRA holds $97.7M in cash and short-term investments and burns about $18.7M/quarter from operations, an estimated runway of 15.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 18 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ETRA files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ETRA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →